Working… Menu

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03091257
Recruitment Status : Recruiting
First Posted : March 27, 2017
Last Update Posted : August 13, 2019
Multiple Myeloma Research Consortium
Barbara Ann Karmanos Cancer Institute
Information provided by (Responsible Party):
Noopur Raje, Massachusetts General Hospital

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2021